Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 1 2

Status

Unknown 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2OTHER_GOV 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 5Thoracic 3Lymphoid 3Other hematologic neoplasm 2Breast 2Tumor-Agnostic 1Sarcoma 1Gynecologic 1Gastrointestinal 1Classical hematology 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Metabolism, Inborn Errors 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Non-Hodgkin 1Leukemia 1Immunologic Deficiency Syndromes 1Immunoblastic Lymphadenopathy 1Hemoglobinopathies 1Congenital Bone Marrow Failure Syndromes 1Bone Marrow Failure Disorders 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Rituximab 169Cyclophosphamide 158fludarabine 76Lenalidomide 73Vincristine 70fludarabine phosphate 63Etoposide 59Doxorubicin 56Prednisone 54venetoclax 49Cytarabine 48Dexamethasone 43Filgrastim 39Peripheral Blood Stem Cell Transplantation 38Methotrexate 38Bendamustine Hydrochloride 38ibrutinib 37obinutuzumab 36Gemcitabine 31pembrolizumab 27Melphalan 27Bortezomib 27Alemtuzumab 25Radiotherapy 23Nivolumab 21Carboplatin 21Tacrolimus 20Granulocyte Colony-Stimulating Factor 20Busulfan 20Whole-Body Irradiation 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Clinical Trials, Phase I as Topic × Lymphoid × Clear all
NCT06839456 2026-04-15

Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT

Children's Hospital of Philadelphia

Phase 1/2 Recruiting
100 enrolled
Classical hematologyLymphoidOther hematologic neoplasm

Bone Marrow Failure Disorders, Congenital Bone Marrow Failure Syndromes, Anemia, Refractory, with Excess of Blasts, Hemoglobinopathies, Immunologic Deficiency Syndromes, Leukemia, Lymphoma, Non-Hodgkin, Metabolism, Inborn Errors

NCT02223208 2025-12-02

FIL_PTCL13

Fondazione Italiana Linfomi - ETS

Phase 1/2 Active not recruiting
89 enrolled
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Peripheral

NCT05429905 2023-03-09

Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) for Relapsed Refractory B-Lineage Leukaemia

KK Women's and Children's Hospital

Phase 1/2 Unknown
48 enrolled
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡